Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Feb. 3, 1997

Japanese researchers describe compounds for lipoprotein disorders

Feb. 3, 1997

FDA approves Teva drug

Jan. 31, 1997

FDA approves antidiabetic drug within 6 months of filing

Jan. 31, 1997

Biotech launches Diab II

Jan. 31, 1997

Shaman describes antidiabetic agents from natural source

Jan. 31, 1997

Takeda researches follow-up compounds to leuprorelin

Jan. 31, 1997

Mixed CCK-A agonist/CCK-B antagonist from Glaxo Wellcome

Jan. 30, 1997

NutraGenics changes name, receives patent coverage for proprietary technology

Jan. 30, 1997

Pfizer reveals agents for hypercholesterolemia, atherosclerosis

Jan. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 30, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026